Wie hoch ist der Preis für Metagenomi, Inc. Common Stock (MGX)

Preis für Metagenomi, Inc. Common Stock (MGX) ist $1.21

Wie hoch ist die Marktkapitalisierung für Metagenomi, Inc. Common Stock (MGX)

Marktkapitalisierung für Metagenomi, Inc. Common Stock (MGX) ist $45.55M

Metagenomi, Inc. Common Stock (MGX) Aktiensplits

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.